tiprankstipranks
Trending News
More News >
Vimian Group AB (SE:VIMIAN)
:VIMIAN

Vimian Group AB (VIMIAN) AI Stock Analysis

Compare
0 Followers

Top Page

SE

Vimian Group AB

(Frankfurt:VIMIAN)

Rating:68Neutral
Price Target:
kr50.00
▲(14.05%Upside)
Vimian Group AB demonstrates strong financial performance with solid revenue and profit growth, efficient operations, and robust cash flow generation. However, the technical indicators suggest potential overbought conditions, and the high P/E ratio raises concerns about overvaluation. The absence of dividend yield also detracts from its investment appeal.
Positive Factors
Market Listing
Vimian's approval to list on the Nasdaq Stockholm Main Market in the Large Cap segment is expected to improve share liquidity and elevate the company's profile.
Profitability
Vimian's profitability exceeded expectations with a significant increase in net sales and strong organic growth across key segments.
Negative Factors
MedTech Performance
MedTech experienced a decline in organic growth due to the final phase-out of the AOP and challenges in the US surgery market.
Profit Margins
The adjusted EBITA margin decreased, reflecting the effects of R&D capitalization, a write-off in Specialty Pharma, and increased investments in marketing and sales.

Vimian Group AB (VIMIAN) vs. iShares MSCI Sweden ETF (EWD)

Vimian Group AB Business Overview & Revenue Model

Company DescriptionVimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name. It also provides procurement and tech-driven operations, such as online marketing, and education and HR, as well as a community for veterinary clinics through a membership-based platform under the VetFamily brand name; and orthopedic implants for veterinarians and universities under the Movora brand name. The company was incorporated in 2020 and is headquartered in Stockholm, Sweden.
How the Company Makes MoneyVimian Group AB generates revenue through its diversified operations across multiple sectors in the animal health industry. Its revenue streams include the sale of specialty pharmaceuticals that address specific health issues in animals, diagnostics products that aid in the identification of diseases, and advanced technology solutions that improve veterinary practice efficiency. Additionally, Vimian provides veterinary services that offer direct support and expertise to animal health practitioners. The company benefits from strategic partnerships and collaborations with veterinary clinics, research institutions, and other healthcare entities that enhance its market presence and drive sales growth.

Vimian Group AB Financial Statement Overview

Summary
Vimian Group AB shows a robust financial performance with consistent revenue and profit growth. The company maintains a healthy balance sheet with moderate leverage and strong equity support. Cash flow generation is strong, enhancing the company's liquidity position.
Income Statement
82
Very Positive
The company has demonstrated consistent revenue growth over the years, with a significant increase in total revenue from 2020 to TTM 2025. Gross Profit Margin is strong, and there is a notable improvement in Net Profit Margin over the periods, indicating enhanced profitability. The EBIT and EBITDA margins are also favorable, reflecting efficient operations.
Balance Sheet
75
Positive
The balance sheet shows a solid equity base with a consistent increase in stockholders' equity over time. The Debt-to-Equity Ratio is moderate, suggesting manageable leverage. The Equity Ratio indicates a stable financial structure, although there has been a gradual increase in total debt.
Cash Flow
78
Positive
The cash flow statement reflects strong Free Cash Flow growth, particularly from 2023 to TTM 2025, demonstrating effective cash management. Operating Cash Flow has also improved significantly, supporting the company's ability to generate cash relative to net income.
Breakdown
TTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
391.04M374.80M331.73M281.31M173.35M137.75M
Gross Profit
269.89M258.30M229.43M193.99M122.85M95.52M
EBIT
51.41M49.20M41.27M39.36M21.60M74.80M
EBITDA
87.04M82.80M69.19M66.32M40.98M65.16M
Net Income Common Stockholders
19.25M18.50M9.84M-7.20M6.59M52.79M
Balance SheetCash, Cash Equivalents and Short-Term Investments
37.50M64.80M37.50M42.19M55.11M29.66M
Total Assets
973.68M1.11B973.68M923.56M640.72M456.29M
Total Debt
313.80M233.60M313.80M220.96M180.37M85.91M
Net Debt
276.30M168.80M276.30M178.76M125.25M56.24M
Total Liabilities
446.97M403.30M446.97M442.06M282.08M182.05M
Stockholders Equity
526.37M699.90M526.37M481.81M357.41M224.02M
Cash FlowFree Cash Flow
51.92M43.90M-43.48M15.01M4.52M-793.00K
Operating Cash Flow
64.07M58.10M-28.58M25.31M16.01M4.80M
Investing Cash Flow
-82.54M-76.00M-77.68M-188.53M-115.00M-105.24M
Financing Cash Flow
39.69M44.80M100.55M150.23M123.94M118.57M

Vimian Group AB Technical Analysis

Technical Analysis Sentiment
Positive
Last Price43.84
Price Trends
50DMA
39.94
Positive
100DMA
40.12
Positive
200DMA
41.48
Positive
Market Momentum
MACD
1.27
Negative
RSI
58.77
Neutral
STOCH
57.47
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:VIMIAN, the sentiment is Positive. The current price of 43.84 is above the 20-day moving average (MA) of 41.41, above the 50-day MA of 39.94, and above the 200-day MA of 41.48, indicating a bullish trend. The MACD of 1.27 indicates Negative momentum. The RSI at 58.77 is Neutral, neither overbought nor oversold. The STOCH value of 57.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:VIMIAN.

Vimian Group AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
68
Neutral
€22.70B103.323.18%16.00%126.41%
54
Neutral
$5.37B3.35-45.10%2.79%16.77%-0.01%
kr19.09B80.292.43%4.84%
kr20.87B41.973.79%0.69%
$2.48B85.815.83%0.35%
$1.84B160.2118.01%
€3.76M-139.61%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:VIMIAN
Vimian Group AB
43.84
8.74
24.90%
GB:0O5H
Elekta AB
49.38
-15.18
-23.51%
GB:0YAY
Vitrolife AB
154.33
-29.30
-15.96%
ADDLF
AddLife AB
20.36
8.20
67.43%
BOEUF
BONESUPPORT HOLDING AB
27.94
-1.04
-3.59%
DE:PGO0
Prostatype Genomics AB
0.08
-0.32
-80.00%

Vimian Group AB Corporate Events

Vimian Group AB Adopts New Incentive Programs and Remuneration Guidelines
Jun 11, 2025

Vimian Group AB held an Extraordinary General Meeting on June 11, 2025, where shareholders approved several key resolutions. These included adopting new Articles of Association to introduce reclassifiable and redeemable share classes for the company’s incentive program, implementing a long-term performance-based share program for employees and consultants, and updating remuneration guidelines to allow for incentive programs to be adopted by both Annual and Extraordinary General Meetings. These changes are expected to enhance Vimian’s operational flexibility and align with local laws and practices, potentially impacting its market positioning and stakeholder relations.

The most recent analyst rating on (SE:VIMIAN) stock is a Buy with a SEK55.00 price target. To see the full list of analyst forecasts on Vimian Group AB stock, see the SE:VIMIAN Stock Forecast page.

Vimian Group AB Successfully Issues EUR 150 Million in Bonds
May 13, 2025

Vimian Group AB has successfully issued EUR 150 million in senior unsecured bonds, significantly oversubscribed, with plans to list them on Nasdaq Stockholm. This move reflects strong investor confidence and is expected to enhance Vimian’s financial flexibility, supporting its growth in the animal health sector.

The most recent analyst rating on (SE:VIMIAN) stock is a Buy with a SEK55.00 price target. To see the full list of analyst forecasts on Vimian Group AB stock, see the SE:VIMIAN Stock Forecast page.

Vimian Group AB Plans EUR 125 Million Bond Issuance
May 9, 2025

Vimian Group AB is considering issuing a senior unsecured bond to raise EUR 125 million, with a potential framework of EUR 250 million, subject to market conditions. The proceeds will be used to refinance existing debt and support corporate activities, including acquisitions and investments, potentially impacting its financial strategy and market positioning.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.